zoliflodacin

a DNA gyrase inhibitor for treatment of gonorrhea

Also Known As:

(2R,4S,4AS)-11-fluoro-2,4-dimethyl-8-((4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'H,6H-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'H,3'H)-trione; AZD-0914; AZD0914; ETX-0914; ETX0914

Networked: 21 relevant articles (5 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Unemo, Magnus: 8 articles (01/2022 - 09/2014)
2.	Golparian, Daniel: 6 articles (01/2022 - 09/2014)
3.	Jacobsson, Susanne: 6 articles (01/2022 - 09/2014)
4.	Basarab, Gregory S: 4 articles (12/2022 - 07/2015)
5.	Mueller, John: 4 articles (11/2021 - 09/2014)
6.	Mueller, John P: 4 articles (12/2020 - 07/2015)
7.	Alm, Richard A: 4 articles (01/2016 - 09/2014)
8.	Drusano, George: 3 articles (01/2022 - 12/2019)
9.	Alirol, Emilie: 3 articles (01/2021 - 09/2019)
10.	Lawrence, Kenneth: 3 articles (11/2018 - 07/2015)

Related Diseases

1.	Gonorrhea 11/17/2021 - "Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults." 11/08/2018 - "In this multicenter, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea. " 09/01/2015 - "Additional studies investigating the in vitro and in vivo induction and mechanisms of ETX0914 resistance in gonococci, pharmacokinetics/pharmacodynamics in modeling/simulations and in humans, and performance in randomized controlled gonorrhea treatment trials are essential. " 03/16/2023 - "Zoliflodacin is a promising novel antimicrobial in clinical development for treatment of gonorrhea; currently, it is in a global phase 3 randomized controlled clinical trial. " 01/13/2023 - "The current phase III clinical trial of zoliflodacin for gonorrhea is due to be read out in 2023. "
2.	Infections 12/01/2020 - "In a phase 2 study, zoliflodacin was effective in treating gonococcal urogenital and rectal infections. " 01/01/2022 - "Using our newly developed Hollow Fiber Infection Model (HFIM), the pharmacodynamics of zoliflodacin was examined. " 01/01/2022 - "Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model." 01/01/2021 - "Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model." 01/01/2019 - "aureus infection, 33e exhibited superior in vivo efficacy (ED50 = 3.87 mg/kg) compared to ETX0914 (ED50 = 11.51 mg/kg)."
3.	Sexually Transmitted Diseases (Sexually Transmitted Disease) 12/01/2019 - "Zoliflodacin, alone or in combination with sexually transmitted infection therapeutic antimicrobials, rapidly kills gonococci with infrequent resistance emergence. " 01/01/2015 - "ETX0914, monotherapy or in combination with azithromycin (to cover additional sexually transmitted infections), should be considered for phase III clinical trials and future gonorrhea treatment. "
4.	Urethritis 01/01/2016 - "We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013. "
5.	Staphylococcal Infections 07/14/2015 - "Preclinical evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine Staphylococcus aureus infection model that served as a surrogate for predicting efficacious exposures for the treatment of Neisseria gonorrhoeae infections. "

Related Drugs and Biologics

1.	DNA Gyrase
2.	Ceftriaxone (Ceftriaxon)
3.	zoliflodacin
4.	DNA Topoisomerase IV (Topoisomerase IV)
5.	Azithromycin (Zithromax)
6.	Anti-Bacterial Agents (Antibiotics)
7.	Topoisomerase II Inhibitors
8.	A-Form DNA (A-DNA)
9.	Fluoroquinolones
10.	Bacterial DNA

Related Therapies and Procedures

1.	Therapeutics